-
Clarithromycin CYP3A Inhibitor Workflow
2026-09-15
Build reproducible CYP3A inhibition assays with Clarithromycin SKU A4322, from solvent handling and controls to LC-MS interpretation. The workflow also shows how a CYP-independent anticoagulant reference model can sharpen drug-drug interaction research without overstating translational evidence.
-
Helper Lipids in Self-Amplifying RNA Nanoparticles
2026-09-15
Barbieri et al. systematically examined how helper-lipid identity interacts with ionisable lipids to control self-amplifying RNA nanoparticle potency, immunogenicity, and storage stability. The study identifies C12–200 combined with DSPC as a strong formulation balance, while showing that cell-culture expression alone does not reliably predict ex vivo or in vivo performance.
-
GW 6471 Workflows for PPARα Mechanism Studies
2026-09-14
Use GW 6471 to move PPARα research from pathway association to causal testing across hepatotoxicity, lipid regulation, and cellular metabolism models. This practical guide combines exposure design, multi-readout validation, troubleshooting, and limitations for translating zebrafish findings into focused mechanistic assays.
-
Carrier-Platin and ROS-Driven Cancer Cell Death
2026-09-14
The reference study introduces carrier-platin, a poly(amino acids)-based formulation containing ultrasmall platinum nanoparticles that catalytically generates a rapid intracellular reactive oxygen species burst. Its reported DNA-damage-independent, nonapoptotic, and nonferroptotic mechanism distinguishes it from conventional platinum chemotherapy and suggests a strategy for addressing multidrug-resistant tumors.
-
5-Aminolevulinic acid HCl: Heme Pathway Guide
2026-09-13
5-Aminolevulinic acid HCl is the hydrochloride salt of 5-amino-4-oxopentanoic acid and an intermediate in heme biosynthesis. Its conversion toward protoporphyrin IX supports biochemical assays, photodynamic research, and fluorescence-guided tumor resection, while Salmonella evidence shows that pathogen-derived haem can affect macrophage phagocytosis.
-
CTOP as a Causal Probe of μ-Opioid Signaling
2026-09-12
CTOP is a selective μ-opioid receptor antagonist for testing whether opioid-driven cellular, circuit, and behavioral effects truly depend on MOR activation. This article translates a 2024 brain-to-spinal pain study into a causality-focused framework for receptor binding studies and neuropharmacology experiments.
-
Ruxolitinib, DRP1, and Pyroptosis in ATC
2026-09-12
A 2024 Cell Death and Disease study identifies a mechanistic link between JAK1/2–STAT3 signaling, DRP1-dependent mitochondrial fission, and dual apoptotic–pyroptotic death in anaplastic thyroid carcinoma. The findings position ruxolitinib as a useful preclinical probe for testing how transcriptional control of mitochondrial dynamics influences ATC cell fate.
-
Thermal-Protective Hydrogel for Curative Tumor Ablation
2026-09-11
The reference study presents an injectable MR@CaP@HA hydrogel that addresses two linked limitations of thermal ablation: collateral heat injury and weak immune control of residual tumor cells. By combining local thermal insulation with pH- and glutathione-responsive delivery of mitoxantrone and R-848, the platform improved immune activation and produced complete tumor eradication in a subset of treated animals.
-
MitMAB Workflows for Organoid Endocytosis
2026-09-11
MitMAB enables time-resolved testing of dynamin-dependent uptake in polarized intestinal organoids, where bulk fluorescence alone can obscure epithelial orientation. This practical workflow connects inhibitor treatment, milk-derived extracellular vesicle tracking, and region-specific controls to distinguish impaired internalization from labeling, polarity, or toxicity artifacts.
-
NSC 87877: Practical Shp2 Inhibitor Workflows
2026-09-10
NSC 87877 combines potent Shp2/Shp1 inhibition with practical applications in EGF–Erk signaling, microglial inflammation, leukemia biology, and pain research. This workflow-oriented guide covers assay setup, concentration selection, orthogonal validation, and troubleshooting while distinguishing product-supported findings from proposed starting conditions.
-
β-Elemene: 3T3-L1 Assay Workflow Guide
2026-09-10
Use β-Elemene as a mechanism-oriented tool for connecting adipocyte differentiation, insulin-resistance modeling, lipid accumulation, and AMPK pathway validation. This workflow combines literature-backed dosing with practical controls, solvent guidance, and troubleshooting for more reproducible metabolic assays.
-
Macrophage EV miR-660 Drives Breast Cancer Metastasis
2026-09-09
The reference study identifies a macrophage-to-tumor communication mechanism in which extracellular-vesicle miR-660 activates the KLHL21–IKKβ/NF-κB p65 axis and promotes breast cancer invasion and metastasis. Its combination of patient tissue analysis, EV transfer experiments, molecular perturbation, and mouse modeling provides a useful framework for studying tumor-microenvironment signaling.
-
Losmapimod and the Next Era of p38 Signaling
2026-09-09
Losmapimod, also known as GW856553X, offers translational researchers a way to study p38α/β inhibition alongside conformationally controlled kinase dephosphorylation. This thought-leadership analysis connects the mechanism to inflammation signaling modulation, vascular biology, hypertension research, and chronic obstructive pulmonary disease research while emphasizing experimentally testable boundaries.
-
Go 6983 and the PKC Logic of Translational Research
2026-09-08
Go 6983 is more than a broad PKC pathway probe: it can help translational researchers test whether PKC activity connects cell-state changes to neuronal excitability, cancer progression, and epithelial plasticity. This thought-leadership guide integrates findings from Neuroligin 1–deficient striatal D2-MSNs with practical experimental strategy, assay controls, and a realistic view of pharmacological translation.
-
Dynasore in Reliable Cell Assay Workflows
2026-09-08
Learn how Dynasore, SKU A1605, can be incorporated into viability, proliferation, cytotoxicity, and endocytosis experiments without confusing pathway-specific effects with assay artifacts. This scenario-based guide covers mechanism, controls, preparation, interpretation, and practical supplier-selection criteria.